248 results - Mindscape Collective

Oral and Sublingual Ketamine (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 10 participants Western University, Canada

Major Depression Severe

Psilocybin for Treatment of OCD-2 (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1/2 20 participants Francisco A Moreno

Obsessive - Compulsive Disorder

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1/2 48 participants Manoj Doss

Healthy

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 20 participants Jon Dean

Healthy Participants Study

Pregnenolone for Cannabis Use Disorder and Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1/2 20 participants University of Texas Southwestern Medical Center

Cannabis Use Disorder, Major Depressive Disorder (MDD)

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 50 participants Gabriella Gobbi

Healthy Participants, Placebo - Control, Psilocybin

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 120 participants University of Wisconsin, Madison

Well-Being, Psychological, Psychedelic Experiences

The Effects of Psilocybin on Social Connectedness (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 51 participants Yale University

Loneliness, Grief

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1/2 50 participants Indiana University

Treatment Resistant Depression, Substance Use Disorders

Psilocybin Efficacy With or Without Pimavanserin Pretreatment (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1/2 20 participants Johns Hopkins University

Mood (Psychological Function), Well Being, Mood, Healthy

Shortened LSD Intervention for Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 10 participants Johns Hopkins University

Major Depression Moderate, Major Depression Severe, Major Depression

Psilocybin After Trauma Surgery for Pain (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 70 participants Trent Emerick

Pain Management, Postoperative Pain

Psilocybin as a Novel Therapy for Residual Anhedonia (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 90 participants NYU Langone Health

Anhedonia, Emotional Blunting

Cannabidiol Oil for Treatment-Resistant Major Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1/2 120 participants Universidade do Sul de Santa Catarina

Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)

A Study of Psychedelics in Healthy Older Adults With Low Well-being (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 80 participants Jennifer Mitchell

Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)

MDMA Assisted Therapy for BN (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 40 participants Icahn School of Medicine at Mount Sinai

Bulimia Nervosa

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 30 participants Francisco A Moreno

Obsessive-Compulsive Disorder

Psilocybin to Treat Depression in Spinal Cord Injury (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1/2 30 participants James J. Peters Veterans Affairs Medical Center

Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 36 participants University of New Mexico

PTSD

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 15 participants Gustavo Vazquez

Demoralization, Safety

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 12 participants GH Research Ireland Limited

Healthy Adult

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 40 participants University of Colorado, Denver

Healthy Volunteer, Older Adults (65-85 Years)

Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 40 participants University Hospital, Basel, Switzerland

5-methoxy-dimethyltryptamine (5-MeO-DMT)

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 1 16 participants Resilient Pharmaceuticals

Pharmacokinetics, Hepatic Impairment

Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 1 20 participants University Hospital, Basel, Switzerland

Healhty